Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11729902 | 0.76 | PDK2 (0.38) | ALDH1A1POLBMEN1KMT2AGAA | |
| SCHEMBL6881522 | 0.71 | ALDH1A1 (0.43) | ALDH1A1POLBMEN1KMT2AGAA | |
| SCHEMBL6883483 | 0.71 | POLB (0.36) | ALDH1A1POLB | |
| SCHEMBL6865405 | 0.68 | KDM1A (0.36) | POLBMEN1KMT2AGAAKDM1A | |
| SCHEMBL13109889 | 0.68 | SLC6A4 (0.35) | — | |
| SCHEMBL13109887 | 0.68 | PDK2 (0.43) | ALDH1A1POLBMEN1KMT2AGAA | |
| SCHEMBL24736532 | 0.67 | BACE1 (0.41) | ALDH1A1POLBMEN1KMT2AGAA | |
| SCHEMBL31306861 | 0.67 | CYP2D6 (0.36) | ALDH1A1POLBMEN1KMT2AGAA | |
| SCHEMBL17203069 | 0.66 | BACE1 (0.44) | ALDH1A1POLBMEN1KMT2AGAA | |
| SCHEMBL17202972 | 0.64 | HTR2A (0.43) | ALDH1A1POLBMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | ALDH1A1 77/4885POLB 2103/4885MEN1 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.